Domain Therapeutics SA
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2001-01-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Immune checkpoint inhibitor
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Domain Therapeutics Australia Pty Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06819735
- Locations
- 🇦🇺
Peninsula & South Eastern Haematology & Oncology Group, Frankston, Victoria, Australia
🇦🇺Cabrini Health Limited, Malvern, Victoria, Australia
DT-9081 Study in Participants with Advanced, Recurrent or Metastatic Solid Tumours
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: DT-9081 - dose escalationDrug: DT-9081 - expansion
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Domain Therapeutics SA
- Target Recruit Count
- 48
- Registration Number
- NCT05582850
- Locations
- 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪Université Catholique de Louvain, Louvain, Belgium
🇫🇷Institut Curie, Paris, France
News
No news found